The recent announcement by Brisbane based Progen that they would discontinue their PI-88 drug development comes as a wake up call for the entire Biotech industry.
The Board of Progen announced that the reasons underlying this about face in strategy were based on issues around patient recruitment, regulatory issues and clinical site initiation amongst others. We [...]

[Read more →]

When you talk to people about innovation, the conversation has a habit of always drifting to ideas, developing ideas and the search for the ‘big idea’. The idea that will make them rich, bust up the competition and rearrange the market as we know it.
Within many of the large corporates ‘innovation’ invariably ends up [...]

[Read more →]